🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

82 results for “doxorubicin” Clear

  1. VINCRISTINE , MELPHALAN , DOXORUBICIN , CYCLOPHOSPHAMIDE , IFOSFAMIDE , Trecondi 1 g powder for solution for infusion, ETOPOSIDE , Trecondi 5 g powder for solution for infusion

    Fondazione Telethon ETS

    Ewing Sarcoma

    phase 2 small molecule active

    1 trial

  2. Yondelis 1 mg powder for concentrate for solution for infusion, DOXORUBICINE ARROW 2 mg/ml, solution pour perfusion

    Cancer Prevention Pharma (Ireland) Limited

    Localized, resected, FIGO stage I (2018 classification), uterine leiomyosarcoma

    phase 2 small molecule active

    1 trial

  3. A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL)

    Roche Registration Limited

    Diffuse large B-cell lymphoma (DLBCL), Grade 3B follicular lymphoma, High grade B-cell lymphoma (HGBL), Epstein-Barr virus−positive DLBCL

    phase 1 other active

    1 trial

  4. Doxorubicin

    United Therapeutics Europe Ltd

    Pancreatic Ductal Adenocarcinoma

    phase 1 small molecule terminated

    1 trial

  5. Single agent of cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate

    China SXT Pharmaceuticals

    Breast Cancer

    phase 1 small molecule active

    1 trial

  6. ZIO-201-T and doxorubicin

    Alaunos Therapeutics

    Advanced Cancer

    phase 1 small molecule completed

    1 trial

  7. Doxorubicin Accord 2 mg/ml koncentrat till infusionsvätska, lösning, Paclitaxel Accord 6 mg/ml koncentrat till infusionsvätska, lösning, Docetaxel Ebewe 10 mg/ml koncentrat till infusionsvätska, lösning, Epirubicin Accord 2 mg/ml injektions-/infusionsvätska, lösning, Sendoxan pulver till injektionsvätska, lösning

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Breast cancer female NOS

    approved small molecule active

    1 trial

  8. PDD regimen: doxorubicin hydrochloride iposome, bortizomib and dexamethasone

    First Tracks Biotherapeutics

    Multiple Myeloma

    approved small molecule active

    1 trial

  9. Pegylated liposomal doxorubicin

    First Tracks Biotherapeutics

    Breast Cancer

    approved small molecule active

    1 trial

  10. Liposomal Doxorubicin

    United Therapeutics Europe Ltd

    Ovarian Cancer

    small molecule terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources